AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04035070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTAD
Description: mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
Study NCT04035070 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% sodium hypochlorite
Description: It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
Study NCT05739786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liq nitrogen
Description: In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
Study NCT05739786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intralesional vitamin D3
Description: Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of > 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
Study NCT04640610 — intervention group
Intervention type: OTHER
Intervention: Storage of operating waste
Description: Storage of operating waste of adenoidectomy / tonsillectomy
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taken by mouth (PO)
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Taken by mouth (PO)
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Taken by mouth (PO)
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Taken by mouth (PO)
Study NCT04972396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol and Levonorgestrel
Description: Taken by mouth (PO)
Study NCT05654597 — intervention group
Intervention type: OTHER
Intervention: CAPTURE tool
Description: CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
Study NCT05654597 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
Study NCT06218095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation application
Description: Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chort 1 of M802
Description: Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chort 2 of M802
Description: Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 of M802
Description: Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 of M802
Description: Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 of M802
Description: Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6 of M802
Description: Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7 of M802
Description: Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
Study NCT04501770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 8 of M802
Description: Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
Study NCT04935099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
Study NCT04935099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
Study NCT04350775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RE-IADL
Description: RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
Study NCT04350775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General community rehabilitation
Description: General community rehabilitation contains the activities in psychiatric rehabilitation center.
Study NCT04648605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post traumatic stress disorder questionnaire
Description: Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
Study NCT04772040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Fish oil capsules.
Study NCT06095661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.
Description: The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
Study NCT05017207 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
Study NCT05432882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR CD19/22 T cells
Description: Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
Study NCT06503575 — intervention group
Intervention type: OTHER
Intervention: Assesment
Description: All assessments will be made
Study NCT05023408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin Injection
Description: Intralesional Bleomycin used for treatment of cutaneous warts.
Study NCT05023408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy used for comparison of efficacy.
Study NCT05884931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexpowder
Description: Hemostatic powder for endoscopy after colonoscopy polypectomy
Study NCT05884931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Standard hemostatic procedure
Study NCT05975606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be applied to primary motor cortex of the brain.
Study NCT05975606 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: functional electrical stimulation (FES) cycling
Description: FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
Study NCT05975606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation (FES) cycling
Description: FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
Study NCT03681314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
Study NCT05605002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
Study NCT05605002 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
Study NCT05605002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
Study NCT05605002 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
Study NCT05605002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
Study NCT04678570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled.
Study NCT04678570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling Method
Description: The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
Study NCT05291676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
Study NCT05291676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
Study NCT05291676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
Study NCT05291676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad
Description: Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
Study NCT05574595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music theraphy
Description: In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
Study NCT06439212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger powder capsule
Description: Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
Study NCT06439212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
Study NCT06451445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (NanoKnife)
Description: Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
Study NCT04782544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buttermilk Powder
Description: Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
Study NCT04782544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anhydrous Milk Fat
Description: Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
Study NCT05947487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70-targeting CAR-T cells
Description: Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;
Study NCT05091463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostim-5/Neostim transcutaneous spinal stimulator
Description: Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
Study NCT05807360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops
Description: Hyaluronic acid (HA)-based eyedrops
Study NCT05798442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone health application (Opulse)
Description: The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
Study NCT05913661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
Study NCT05913661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: The dosing regimen is 200 mg IV Q3W
Study NCT05418400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X
Description: dental filling materials
Study NCT06389864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
Study NCT06389864 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
Study NCT05953142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
Study NCT06496282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
Study NCT06496282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
Study NCT05754385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory monitoring of liver fat
Description: Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
Study NCT05754385 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Subjects will have follow-up every 6 months by hepatologists for routine care
Study NCT05021107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDM with isometrics
Description: FDM with isometrics will be done
Study NCT05021107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FDM without isometrics
Description: FDM without isometrics will be done